Mutual funds are subject to market risk. Read all scheme documents carefully.
The fund is rated 4.5 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Above-average fund size of Rs 101,856.06 crore was a minor drawback.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 101856.06 AUM and a 1.31 expense ratio. Considering all these factors, we have rated this fund as 4.5 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 9 Nov 2026
As of 31 Oct 2026
to generate long-term capital appreciation / income. investment predominantly in Mid-Cap companies.
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies.
Exit load of 1% if redeemed within 1 year.
As of 30 Sep 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| The Federal Bank Ltd. | 3.98% | ₹4,057.17 Cr | 12,78,25,000 |
| AU Small Finance Bank Ltd. | 3.94% | ₹4,014.66 Cr | 3,97,37,347 |
| Max Financial Services Ltd. | 3.52% | ₹3,586.53 Cr | 2,61,14,231 |
| Ipca Laboratories Ltd. | 3.43% | ₹3,495.71 Cr | 1,81,40,659 |
| Glenmark Pharmaceuticals Ltd. | 3.07% | ₹3,130.41 Cr | 1,34,08,183 |
| Balkrishna Industries Ltd. | 2.98% | ₹3,036.04 Cr | 1,43,41,251 |
| Indian Bank | 2.92% | ₹2,970.1 Cr | 3,68,54,482 |
| Coforge Ltd. | 2.68% | ₹2,732.2 Cr | 1,56,20,600 |
| Fortis Healthcare Ltd. | 2.40% | ₹2,441.04 Cr | 3,17,01,862 |
| Marico Ltd. | 2.37% | ₹2,411.17 Cr | 3,06,76,407 |
